Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY) | RFA DP 25 043

Opportunity Information: Apply for RFA DP 25 043

The Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY) is a CDC cooperative agreement funding opportunity (RFA DP 25 043; CFDA 93.945) focused on strengthening nationwide surveillance of diabetes among children, adolescents, and younger adults. The program is built around the idea that large health systems and health plan membership-based settings can provide high-quality, population-based data that allow public health agencies to track how many young people have diabetes, how many are newly diagnosed each year, and how diabetes outcomes differ across communities. Through this initiative, CDC is seeking to generate consistent, comparable estimates that can be broken down in practical ways that matter for equity, planning, and prevention, including by diabetes type, demographic characteristics, insurance coverage, and geography.

The first major goal of CASSIDY is to estimate incidence and prevalence of diabetes in two age groups: youth under 18 years old and young adults ages 18 through 44. Incidence refers to new cases occurring over a specific period, while prevalence reflects the total number of people living with diabetes at a point in time or over a period. Importantly, the NOFO emphasizes that these estimates should be produced by diabetes type (for example, type 1 and type 2 where feasible), and stratified by demographic traits, health insurance status, and geographic area. The purpose of these detailed breakdowns is to identify disparities in diabetes burden, meaning the program is explicitly oriented toward showing where the disease is rising, which populations are most affected, and where gaps in care or prevention may exist.

The second major goal is to go beyond counting cases and describe the health status and treatment patterns of youth and young adults who already have diabetes. Specifically, CDC is seeking surveillance data on the prevalence of risk factors for diabetes complications, the occurrence of acute and chronic complications, and the use of diabetes medications. In practice, this points to tracking clinically meaningful indicators that can signal future complications (such as risk factors related to cardiovascular or kidney health), documenting events like severe short-term complications as well as longer-term disease impacts, and describing how diabetes is being treated across populations. Together, this information is intended to provide a clearer picture of real-world outcomes and care patterns for younger people with diabetes, not only the number of diagnoses.

CASSIDY is structured into two coordinated components. Component A supports the core surveillance work conducted across participating sites, particularly health systems and/or health plan membership-based centers that can identify covered populations and reliably capture diagnoses, clinical measures, outcomes, and medication use. These Component A sites are expected to generate the incidence, prevalence, disparity-focused stratifications, and complication and medication measures described in the NOFO. While the announcement text provided does not list specific deliverables line-by-line, the design implies ongoing, standardized surveillance outputs that are comparable across multiple sites and suitable for national-level interpretation.

Component B functions as a Coordinating Center, which is meant to ensure that all participating surveillance sites are using standardized approaches. This includes providing infrastructure for common methods, shared analytical techniques, and consistent measures so that results from different systems can be combined or compared without introducing avoidable inconsistencies. The Coordinating Center is also expected to develop validation protocols (to check that diabetes case identification, complication measures, and other key variables are accurate and consistent), serve as a data repository (supporting secure and organized storage and management of surveillance data), and provide statistical expertise. In other words, Component B is responsible for the backbone that makes multi-site surveillance work at scale: harmonization, quality assurance, centralized data support, and advanced analytics.

From an administrative standpoint, this is a discretionary funding opportunity offered by the Centers for Disease Control and Prevention (CDC) through ERA, using the cooperative agreement funding instrument. A cooperative agreement generally means CDC anticipates substantial involvement in the program beyond what is typical for a standard grant, often including collaboration on methods, reporting, and coordination across awardees. The opportunity lists a wide range of eligible applicants, including various levels of government (state, county, city/township, special districts), independent school districts, public and private institutions of higher education, federally recognized tribal governments and other tribal organizations, public housing/Indian housing authorities, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (other than small businesses), small businesses, and other unrestricted entities. This broad eligibility reflects the reality that health data and surveillance capacity may sit in different kinds of institutions, including academic centers, nonprofit research groups, health care organizations, and government partners.

Key timing and award parameters included in the notice are an original closing date of 2025-01-10, an award ceiling of $700,000, and an expectation of six awards. The notice was created on 2024-11-05. Taken together, the initiative is designed to produce a more complete and comparable national surveillance picture of diabetes in people under 45, with special emphasis on youth and young adults, disparities by population and place, and outcomes related to complications and medication use, supported by a central coordinating entity that ensures standardization, validation, and strong statistical rigor across all participating sites.

• The Centers for Disease Control and Prevention - ERA in the health sector is offering a public funding opportunity titled "Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.945.
• This funding opportunity was created on 2024-11-05.
• Applicants must submit their applications by 2025-01-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $700,000.00 in funding.
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Unrestricted.

Apply for RFA DP 25 043

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: